Sept 4, 1967

Fluorouracil-Floxuridine Controversy

Author Affiliations

Rochester, Minn

JAMA. 1967;201(10):780. doi:10.1001/jama.1967.03130100078027

To the Editor:—  Over the past five or more years, a vast expenditure of funds, both federal and private, and considerable investigator time have been devoted to the study of floxuridine (FUDR). The most intense study and the greatest controversy have revolved about the effectiveness of this chemotherapeutic agent in the palliative treatment of advanced carcinoma of the large bowel. Recently, these efforts reached their culmination in the almost simultaneous publication of the results obtained by two large cooperative groups. Each group administered the drug by the intravenous injection technique, and each stated their results were evaluated by objective criteria. The Central Region of the Clinical Drug Evaluation Program1 made a strong plea for further use of floxuridine in colonic cancer with their astonishing objective regression rate of 59%. Perplexing in contrast is the 4% regression rate reported by the Eastern Cooperative Group in Solid Tumor Chemotherapy.2 This